Atossa Therapeutics is a clinical-stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast cancer.
Its lead drug candidate, (Z)-endoxifen, is designed to work in all three areas of the current breast cancer paradigm: the Prevention Window, the Neoadjuvant Phase, and the Adjuvant Phase. It does this by reducing the density of breast tissue, reducing the cancer cell activity before surgery, and reducing the risk of new cancer after surgery.
